BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies for liver disease and neurological disorders, has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. Under the terms of the agreement, BioVie may offer and sell shares of its Class A common stock with an aggregate offering price of up to $25,000,000 through Cantor, acting as sales agent or principal. This offering is in addition to approximately $61,185,567 previously sold under the same sales agreement pursuant to an expiring registration statement. The common stock is listed on the Nasdaq Capital Market under the symbol 'BIVI,' with the last reported sale price being $1.24 per share as of January 18, 2024. The sales may be made in 'at...Show More

BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies for liver disease and neurological disorders, has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. Under the terms of the agreement, BioVie may offer and sell shares of its Class A common stock with an aggregate offering price of up to $25,000,000 through Cantor, acting as sales agent or principal. This offering is in addition to approximately $61,185,567 previously sold under the same sales agreement pursuant to an expiring registration statement. The common stock is listed on the Nasdaq Capital Market under the symbol 'BIVI,' with the last reported sale price being $1.24 per share as of January 18, 2024. The sales may be made in 'at the market offerings' as defined under the Securities Act of 1933. Cantor will receive a fixed commission of 3.0% of the gross proceeds from any shares sold. BioVie has also agreed to provide indemnification and contribution to Cantor for certain liabilities. Investing in BioVie's common stock involves a high degree of risk, and potential investors are advised to carefully review the risks and uncertainties before making any investment.